Peer-Reviewed by Dr. Marcus Vance, MD, PhD
Lead Clinical Pharmacologist, Institute for Clinical Pharmacology & Safety — Board-certified in Clinical Pharmacology & Toxicology. Reviewed for scientific accuracy against current FDA label documentation, WHO technical monographs, and peer-reviewed literature.
The Short Answer
Oral Stromectol (ivermectin) is a prescription-only medication in the United States. It is not available over-the-counter (OTC) at retail pharmacies, and no FDA-approved OTC oral ivermectin product for human use currently exists. This applies equally to the brand-name product and all AB-rated generic formulations. Obtaining oral ivermectin legally in the United States requires a valid prescription from a licensed prescriber.
This page explains the regulatory basis for that classification, the pathway through which a patient may legitimately obtain a prescription, and the patient safety risks associated with attempts to source ivermectin outside the prescription system.
How the FDA Classifies Prescription Drugs
Under the Federal Food, Drug, and Cosmetic Act (FD&C Act), a drug is classified as a prescription (Rx) product when, in the FDA's judgment, it cannot be used safely without the supervision of a licensed practitioner. The criteria include complexity of dosing, potential for serious adverse effects, and the need for a medical diagnosis to use the drug appropriately. Oral ivermectin meets these criteria on several grounds.
Dosing requires weight-based calculation. The approved indications—strongyloidiasis and onchocerciasis—require laboratory confirmation or clinical assessment by a practitioner to diagnose. At elevated doses or in susceptible populations, serious neurological adverse effects are possible. The pharmacogenomic risk factor (ABCB1/MDR1 variants) is not amenable to self-assessment. Taken together, these considerations adequately justify prescription scheduling.
The OTC Switch Process and Why It Has Not Happened
Pharmaceutical manufacturers can petition the FDA for an OTC switch—a regulatory process permitting reclassification of an Rx product to nonprescription status when the drug's safety profile supports self-directed use. Conditions commonly OTC-switched (e.g., proton pump inhibitors, antihistamines, topical antifungals) share characteristics: straightforward self-diagnosis, simple dosing, limited serious adverse event risk, and a strong consumer safety record.
Oral ivermectin has not been the subject of a successful OTC switch petition, and ICPS is unaware of any current FDA-submitted application pursuing that outcome. The indications requiring it—intestinal strongyloidiasis, onchocerciasis—are parasitic diseases that require diagnosis and often post-treatment confirmation. Self-diagnosis would be unreliable. The OTC pathway presupposes a degree of self-care suitability that does not clearly apply to these indications at present.
Topical Formulations: A Partial Exception
Not all ivermectin products are prescription-only. The topical lotion Sklice (0.5% ivermectin) for head lice pediculosis capitis is available without a prescription in certain formulations. Soolantra (1% ivermectin cream), however, remains prescription-only for inflammatory rosacea lesions. These distinctions matter: topical ivermectin applied to intact skin produces minimal systemic absorption and is therefore pharmacokinetically distinct from oral therapy. These products are not substitutes for oral Stromectol, and their OTC or Rx classification tells us nothing about the oral formulation's status.
What Patients Actually Need: Getting a Legitimate Prescription
The process is straightforward. Patients who believe they have a medically appropriate indication consult a licensed physician, nurse practitioner, or physician assistant. The clinician evaluates the clinical picture, orders appropriate diagnostics where indicated, determines whether a prescription is warranted, and issues one if appropriate. The patient then fills the prescription at a licensed pharmacy.
Telehealth platforms have expanded access to prescribers in recent years. A legitimate telehealth consultation is a valid pathway to a prescription, provided the consultation involves a genuine clinical assessment and the prescriber is licensed in the patient's state of residence. The prescription itself must be for an FDA-approved indication or a clinically documented off-label use within the prescriber's scope of practice.
International Availability: A More Complex Picture
Regulatory status for ivermectin varies internationally. In several countries across Latin America, sub-Saharan Africa, and Southeast Asia, oral ivermectin is available OTC or with minimal formality. This reflects different regulatory environments, local parasitic disease prevalence, and public health policies shaped by mass drug administration programs. International OTC status does not translate to U.S. regulatory standing—and importing prescription medications for personal use carries legal risk in many jurisdictions.
Risks of Unsupervised Access Attempts
ICPS has documented a pattern of concern: patients attempting to obtain oral ivermectin outside the prescription system may turn to online pharmacies operating without legitimate licensure, veterinary formulations (which are not appropriate for human use), or compounding pharmacies operating outside regulatory frameworks. Each pathway carries specific risks—from receiving counterfeit or subpotent products, to incorrect dosing with animal-concentration formulations, to outright fraud.
The prescription requirement exists precisely because supervision matters. An informed conversation with a prescriber—one that considers contraindications, drug interactions, patient weight, and clinical indication—is not bureaucratic overhead. It is patient safety infrastructure.